The Panel will be Moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt,
Ph.D.
BERWYN,
Pa., Aug. 1, 2022 /PRNewswire/ -- Annovis Bio,
Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage
clinical drug platform company addressing neurodegenerative
diseases, announced that Maria Maccecchini, Ph.D., Founder,
President, and CEO of Annovis, will be participating on the Systems
Biology of Alzheimer's Disease Panel at the Alzheimer's Association
International Conference (AAIC).
The panel will focus on the need and underpinning rationale for
advancing novel therapeutic approaches for Alzheimer's disease. The
four companies will present their novel approaches as well as their
outlook on developments impacting clinical trials and patients.
The panel is scheduled to take place on August 4th, 2022, at 8-9:15 AM Pacific Time / 11 AM - 12:15 PM Eastern Time. Interested parties
may access a live panel discussion through the AAIC 2022 conference
site and archived webcast of the presentation on the Company's
investor relations website at: www.annovisbio.com.
Details of the panel are as follows:
Panel Moderators:
- Jeffrey Cummings, MD, ScD,
Director of the Chambers-Grundy Center for Transformative
Neuroscience at the University of Nevada, Las
Vegas; Professor of Medicine at Cleveland Clinic Lerner
College of Medicine at Case Western Reserve
University; and Principal Investigator/Director of the
National Institute of General Medical Sciences-funded Center for
Neurodegeneration and Translational Neuroscience.
- Krista Lanctôt, Ph.D., Director of the Neuropsychopharmacology
Research Group at Sunnybrook Research Institute; Professor in the
Departments of Psychiatry, Pharmacology and Toxicology at the
University of Toronto; and researcher
in neuropsychiatric symptoms secondary to central nervous system
pathology, neuroimaging, serum protein, lipid and metabolite
biomarkers, and interventions.
Participants:
- Raymond J. Tesi, MD, President,
CEO, and acting CMO of INmune Bio
- Hans Moebius, MD, Ph.D., CMO of
Athira Pharma
- John Didsbury, Ph.D., Founder,
President, and CEO of T3D Therapeutics
- Maria Maccecchini, Ph.D., Founder, President, and CEO of
Annovis Bio
For more information, please visit
https://aaic.alz.org/overview.asp.
About Buntanetap
Buntanetap (previously known as ANVS401 or Posiphen) is an oral
translational inhibitor of neurotoxic aggregating proteins
(TINAPs), which mode of action leads to lower levels of neurotoxic
proteins and consequently less toxicity in the brain. In a Phase 2a
clinical trial in AD and PD patients, treatment with buntanetap
resulted in statistically significant improvement in motor function
in PD patients and cognition in AD patients. Additionally,
buntanetap was shown to reduce biomarkers associated with AD or PD,
it was well-tolerated and safe, and its pharmacokinetics were found
to be in line with levels measured earlier in humans, meeting
primary, secondary and exploratory endpoints.
About Annovis Bio, Inc.
Headquartered in Berwyn,
Pennsylvania, Annovis Bio, Inc. is a late-stage clinical
drug platform company developing transformative therapies that
treat neurodegenerative disorders such as Alzheimer's disease (AD),
Parkinson's disease (PD) and other chronic and acute
neurodegenerative diseases. The Company believes that it is the
only company developing a drug that inhibits more than one
neurotoxic protein, improves the information highway of the nerve
cell, known as axonal transport, reduces inflammation and protects
nerve cells from dying in chronic and acute neurodegeneration.
Annovis conducted two Phase 2 studies: one in AD patients and one
in both AD and PD patients. In the AD/PD study, buntanetap showed
improvements in cognition and memory in AD as well as body and
brain function in PD patients.
For more information on Annovis Bio, please visit the Company's
website www.annovisbio.com and follow us on LinkedIn and
Twitter.
Forward-Looking Statements
Statements in this press release contain "forward-looking
statements" that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as "anticipate,"
"expect," "believe," "will," "may," "should," "estimate,"
"project," "outlook," "forecast" or other similar words, and
include, without limitation, statements regarding the timing,
effectiveness, and anticipated results of buntanetap clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.'s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the section
titled "Risk Factors" in the Annual Report on Form 10-K for the
year ended December 31, 2021, filed
with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date,
and Annovis Bio, Inc. undertakes no duty to update such information
except as required under applicable law.
Media and Investor Contact:
Nic Johnson
Russo Partners, LLC
(303) 482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/annovis-bio-to-participate-on-alzheimers-association-international-conference-panel-301596707.html
SOURCE Annovis Bio